Pharma Disappointed By New Extension Of EU Signal Detection Pilot
EFPIA Says Further Extension Was Not Expected
Executive Summary
A further extension of the EU signal detection pilot means that certain drug sponsors must keep monitoring the EudraVigilance database on a continuous basis. Industry argues there is enough evidence that this activity brings no additional value, and that current requirements should be replaced with a more proportionate approach.